ADC THERAPEUTICS SA (ADCT) Fundamental Analysis & Valuation

NYSE:ADCT • CH0499880968

4.19 USD
-0.05 (-1.18%)
At close: Mar 5, 2026
4.19 USD
0 (0%)
After Hours: 3/5/2026, 7:32:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ADCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

ADCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. ADCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. ADCT Profitability Analysis

1.1 Basic Checks

  • In the past year ADCT has reported negative net income.
  • ADCT had a negative operating cash flow in the past year.
  • In the past 5 years ADCT always reported negative net income.
  • ADCT had a negative operating cash flow in each of the past 5 years.
ADCT Yearly Net Income VS EBIT VS OCF VS FCFADCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ADCT has a Return On Assets (-57.61%) which is in line with its industry peers.
Industry RankSector Rank
ROA -57.61%
ROE N/A
ROIC N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADCT Yearly ROA, ROE, ROICADCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

  • Looking at the Gross Margin, with a value of 92.73%, ADCT belongs to the top of the industry, outperforming 93.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADCT has declined.
  • The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
ADCT Yearly Profit, Operating, Gross MarginsADCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ADCT Health Analysis

2.1 Basic Checks

  • ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADCT has been increased compared to 1 year ago.
  • Compared to 5 years ago, ADCT has more shares outstanding
  • ADCT has a worse debt/assets ratio than last year.
ADCT Yearly Shares OutstandingADCT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADCT Yearly Total Debt VS Total AssetsADCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ADCT has an Altman-Z score of -7.48. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ADCT (-7.48) is worse than 67.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.48
ROIC/WACCN/A
WACC4.46%
ADCT Yearly LT Debt VS Equity VS FCFADCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 4.63 indicates that ADCT has no problem at all paying its short term obligations.
  • ADCT has a Current ratio (4.63) which is in line with its industry peers.
  • A Quick Ratio of 4.34 indicates that ADCT has no problem at all paying its short term obligations.
  • ADCT has a Quick ratio of 4.34. This is comparable to the rest of the industry: ADCT outperforms 51.92% of its industry peers.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.34
ADCT Yearly Current Assets VS Current LiabilitesADCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADCT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.35% over the past year.
  • The Revenue for ADCT has decreased by -39.09% in the past year. This is quite bad
  • ADCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.48% yearly.
EPS 1Y (TTM)44.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)-39.09%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%-11.03%

3.2 Future

  • Based on estimates for the next years, ADCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.48% on average per year.
  • The Revenue is expected to grow by 33.94% on average over the next years. This is a very strong growth
EPS Next Y13.35%
EPS Next 2Y15.07%
EPS Next 3Y15.48%
EPS Next 5YN/A
Revenue Next Year8.41%
Revenue Next 2Y5.23%
Revenue Next 3Y27.47%
Revenue Next 5Y33.94%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADCT Yearly Revenue VS EstimatesADCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
ADCT Yearly EPS VS EstimatesADCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. ADCT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADCT. In the last year negative earnings were reported.
  • Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADCT Price Earnings VS Forward Price EarningsADCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADCT Per share dataADCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADCT's earnings are expected to grow with 15.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.07%
EPS Next 3Y15.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADCT Dividend Analysis

5.1 Amount

  • No dividends for ADCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADCT Fundamentals: All Metrics, Ratios and Statistics

ADC THERAPEUTICS SA

NYSE:ADCT (3/5/2026, 7:32:18 PM)

After market: 4.19 0 (0%)

4.19

-0.05 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-12
Inst Owners53.83%
Inst Owner Change20.87%
Ins Owners4.96%
Ins Owner Change4.5%
Market Cap519.06M
Revenue(TTM)75.21M
Net Income(TTM)-166.94M
Analysts86.67
Price Target8.16 (94.75%)
Short Float %4.23%
Short Ratio5.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.04%
Min EPS beat(2)18.68%
Max EPS beat(2)21.4%
EPS beat(4)4
Avg EPS beat(4)20.88%
Min EPS beat(4)12.49%
Max EPS beat(4)30.94%
EPS beat(8)6
Avg EPS beat(8)-0.22%
EPS beat(12)7
Avg EPS beat(12)-2.22%
EPS beat(16)10
Avg EPS beat(16)1.26%
Revenue beat(2)1
Avg Revenue beat(2)-1.14%
Min Revenue beat(2)-5.69%
Max Revenue beat(2)3.41%
Revenue beat(4)2
Avg Revenue beat(4)3.11%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)27.51%
Revenue beat(8)3
Avg Revenue beat(8)0.81%
Revenue beat(12)4
Avg Revenue beat(12)-4.76%
Revenue beat(16)7
Avg Revenue beat(16)2.72%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.98%
EPS NQ rev (3m)6.32%
EPS NY rev (1m)0.47%
EPS NY rev (3m)8.09%
Revenue NQ rev (1m)4.13%
Revenue NQ rev (3m)12.75%
Revenue NY rev (1m)1.05%
Revenue NY rev (3m)1.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.61
BVpS-1.92
TBVpS-1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.73%
FCFM N/A
ROA(3y)-48.71%
ROA(5y)-46.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.51%
GM growth 5YN/A
F-Score2
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -79.73%
Cap/Sales 0.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.34
Altman-Z -7.48
F-Score2
WACC4.46%
ROIC/WACCN/A
Cap/Depr(3y)144.88%
Cap/Depr(5y)161.59%
Cap/Sales(3y)2.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y13.35%
EPS Next 2Y15.07%
EPS Next 3Y15.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-39.09%
Revenue growth 3Y27.85%
Revenue growth 5Y98.48%
Sales Q2Q%-11.03%
Revenue Next Year8.41%
Revenue Next 2Y5.23%
Revenue Next 3Y27.47%
Revenue Next 5Y33.94%
EBIT growth 1Y53.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.21%
OCF growth 3YN/A
OCF growth 5YN/A

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

ChartMill assigns a fundamental rating of 2 / 10 to ADCT.


Can you provide the valuation status for ADC THERAPEUTICS SA?

ChartMill assigns a valuation rating of 0 / 10 to ADC THERAPEUTICS SA (ADCT). This can be considered as Overvalued.


Can you provide the profitability details for ADC THERAPEUTICS SA?

ADC THERAPEUTICS SA (ADCT) has a profitability rating of 1 / 10.


How financially healthy is ADC THERAPEUTICS SA?

The financial health rating of ADC THERAPEUTICS SA (ADCT) is 2 / 10.